# Medtronic to invest $47.2M in cardiovascular device plant in Shanghai FTZ

Medtronic will invest about CNY300 million ($47.2 million) to build core cardiovascular device production lines in the Lingang Special Area of Shanghai's free trade zone. Construction is expected to start in June 2022 and wrap up within five years, with annual output capacity worth about CNY300 million in the third year of operation.

- Type: New facility
- Announced: 2022-02-14
- Where: Lingang Special Area, Shanghai, China
- Value: $47.2M
- Status: announced
- Products: cardiovascular devices, cardiac rhythm management devices, CoreValve Evolut Pro transcatheter aortic valve replacement system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Medtronic plc](https://endata.com/companies/19071.md)

## Sources

- [yicaiglobal.com](https://www.yicaiglobal.com/news/medtronic-to-invest-millions-in-core-heart-device-production-in-shanghai-ftz), 2022-02-14: "Medtronic will spend about CNY300 million (USD47.2 million) on the project's initial phase."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.